MicroRNA-372 (miR-372)

MicroRNA-372 (miR-372) is a small, non-coding, endogenous RNA molecule (~22 nucleotides) that regulates gene expression at the post-transcriptional level by binding to complementary sequences in the 3′-UTR of target mRNAs, resulting in mRNA degradation or translation inhibition[1][2][3][4]. Located on chromosome 19q13.42 as part of the miR-371–373 gene cluster, miR-372 plays diverse roles in physiological and pathological processes, including cell proliferation, apoptosis, the cell cycle, migration, invasion, differentiation, and stemness regulation[1][3]. In various human cancers and disease contexts, miR-372 can function as either an oncogene or tumor suppressor, depending on tissue type and molecular environment[1][3][4]. Its abnormal expression and regulatory targets in different malignancies enable its use as a candidate biomarker for diagnosis, prognosis, and patient stratification[1][3]. miR-372 is under investigation as a potential therapeutic target, but clinical pharmacological agents directly targeting miR-372 are not currently available; investigational approaches may involve inhibition (antagomirs) or mimetics to normalize its function[1][3].

Other names

MIR372hsa-mir-372MIRN372microRNA 372miR-372-3pmiRNA-372

Not applicable for traditional drugs; microRNA-based therapeutics may inhibit or mimic miR-372 expression to regulate its target genes.